Recent clinical trials have shown promising results in the treatment of recurrent glioblastoma using engineered CAR T-cell therapy. A first-in-human data study published in Nature reported reductions in tumor size in all six patients at early magnetic resonance imaging timepoints using bivalent CART cells. An interim analysis of a phase 1 trial targeting EGFR and IL13Ra2 in patients with multifocal, recurrent glioblastoma, as mentioned by @StephenBagleyMD, found that intrathecal delivery of CAR T-cells is feasible and well-tolerated. Another study highlighted in @NEJM and @NatureMedicine, revealed a novel CAR T-cell therapy directed at EGFRvIII, showing rapid responses in three patients, although the responses were transient in two of them. These studies underscore the potential of CAR T-cell therapy in treating one of the most aggressive cancers.
Encouraging results for engineered T-cells in 2 new reports for one of there worst cancers—glioblastoma, in recurrence https://t.co/J1URN8Y6yL @NEJM https://t.co/qWT1HmNAuK @NatureMedicine https://t.co/nnKJD3lxZv
A novel CAR T-cell therapy directed at EGFRvIII with a secretable EGFR T-cell engager produced rapid responses in three patients with recurrent glioblastoma, but the responses were transient in two of the three. Read the Brief Report for the full study: https://t.co/kYAm6U9DR1 https://t.co/CoZ4ynAZC0
Spectacular paper in @nature from the excellent Roman Thomas and the @sfb1399 team These insights into the genomic changes in SCLC under therapy offer up the potential for a step-change in therapeutic outcomes - could be the most important paper Ive read since 2015 https://t.co/gd6UCz3ybW
In an interim analysis of a phase 1 trial of #CARTcells targeting EGFR and IL13Ra2 in patients with multifocal, recurrent #glioblastoma, intrathecal delivery is feasible and well tolerated, with some reductions seen in tumor size @StephenBagleyMD https://t.co/QQtqDFnZEK
Recurrent glioblastoma has a median overall survival of less than 1 year. First-in-human data from bivalent #CARTcells clinical trial published in Nature, below. Reductions in tumor size at early magnetic resonance imaging timepoints were observed in all 6 patients. "however,… https://t.co/C5UWUxixLe
Incredible team effort here and this study is still accruing while we monitor durability of these early respknses #glioblastoma #CART cells https://t.co/VtjwWGfJ7O